Oncolytic HSV-1 (genetically modified)
Talimogene laherparepvec (Specialist drug)
Brand names: Imlygic
Adult dose
Dose: Specialist initiation only — refer to BNF/SmPC
Route: Intralesional
Frequency: every 2 weeks
Clinical pearls
- Unresectable stage IIIB-IVM1a melanoma
- Specialist oncology — biosafety precautions
Contraindications
- Severe immunosuppression
- Pregnancy
- Hypersensitivity
Side effects
- Flu-like symptoms
- Injection-site reactions
- Cellulitis
- Herpetic infection (treat with aciclovir)
Interactions
- Aciclovir (reduces efficacy)
- Live vaccines
Monitoring
- Tumour response
- HSV symptoms
Reference: BNF; NICE TA410; SmPC; https://bnf.nice.org.uk/drugs/talimogene-laherparepvec-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Modified Mallampati Classification · Airway Assessment
- Vancomycin Dosing Calculator · Drug Dosing
- Phenytoin Correction for Albumin / Renal Failure · Drug Dosing
- Local Anaesthetic Maximum Dose Calculator · Drug Dosing
- Modified Early Warning Score (MEWS) · Early Warning
- Modified Shock Index (MSI) · Haemodynamic Assessment
Pathways
- Acute Myeloid Leukaemia Presentation · BSH; NICE — NG146
- Tumour Lysis Syndrome · Cairo-Bishop; BSH; NICE — Best Practice
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023